Serious risks exist and are listed below
At present, GSH BIO-TECH has achieved commercial production of products such as glutathione, NMN, and Citicoline Sodium, with an annual production capacity of up to 1000 tons of glutathione
The GLP-1/GIP dual agonist, HRS9531, from Hengrui, reported positive Phase 3 results in weight loss, and is the second (after Innovent) Chinese company to submit marketing authorisation for an obesity asset
Elecoglipron produced clear dose-dependent reductions in body weight
GLP-1 / GIP Programs (Semaglutide or Tirzepatide) Program-based medications sourced from licensed U.S
When compared to common alternatives such as caffeine, conjugated linoleic acid (CLA), or green tea extract, L-carnitine provides a gentler, more sustainable approach to fat metabolism